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Abstract
Background: Sharing de-identified individual-level health research data is widely promoted and has many potential
benefits. However there are also some potential harms, such as misuse of data and breach of participant confidentiality.
One way to promote the benefits of sharing while ameliorating its potential harms is through the adoption of a
managed access approach where data requests are channeled through a Data Access Committee (DAC), rather than
making data openly available without restrictions. A DAC, whether a formal or informal group of individuals, has the
responsibility of reviewing and assessing data access requests. Many individual groups, consortiums, institutional and
independent DACs have been established but there is currently no widely accepted framework for their organization
and function.
Main text: We propose that DACs, should have the role of both promotion of data sharing and protection of data
subjects, their communities, data producers, their institutions and the scientific enterprise. We suggest that data access
should be granted by DACs as long as the data reuse has potential social value and provided there is low risk of
foreseeable harms. To promote data sharing and to motivate data producers, DACs should encourage secondary uses
that are consistent with the interests of data producers and their own institutions. Given the suggested roles of DACs,
there should be transparent, simple and clear application procedures for data access. The approach to review of
applications should be proportionate to the potential risks involved. DACs should be established within institutional
and legal frameworks with clear lines of accountability, terms of reference and membership. We suggest that DACs
should not be modelled after research ethics committees (RECs) because their functions and goals of review are
different from those of RECs. DAC reviews should be guided by the principles of public health ethics instead of
research ethics.
Conclusions: In this paper we have suggested a framework under which DACs should operate, how they should be
organised, and how to constitute them.
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Background
Expectation from health research funders, regulatory agen-
cies, and journals for greater sharing of de-identified
individual-level health research data is now increasing [1–5],
but the volume of data shared remains low [6]. Arguments
in favour of data sharing include maximising the utility of
the data, improving research transparency and allowing con-
firmation of the interpretation of results, with the overall
goal of improving science and health [1, 2, 7, 8]. However,
many have cautioned that there are potential harms with
regards to data sharing, such as misuse of data, breaching
participant confidentiality, group harms of discrimination
and stigmatization, as well as exacerbating existing inequal-
ities between researchers in low- and high-income settings
[2, 9, 10].
There are ongoing discussions on how best to approach
data sharing. The landscape of research ethics is evolving
and after the eras of researcher and regulatory paternalism
[11], a new paradigm shift is being discussed: an ethical
framework for learning healthcare systems [12]. This para-
digm brings a few new ideas. It puts into question the dif-
ference between research and routine clinical practice: new
information technologies alter the nature of medical prac-
tice, which has recently become a learning activity where its
goals are not limited to benefiting an individual patient, but
also embraces the generation of knowledge. The main aim
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of an ethical framework for learning is not to protect indi-
viduals, but to promote the common good of an efficient
and safe healthcare system. Therefore it has been argued
that an ethical framework for learning healthcare systems is
public health ethics [13]. By the same token, it has been
suggested that data sharing should be governed by the prin-
ciples of public health ethics, rather than research ethics
[14]. This is because public health ethics focuses on public
benefit, proportionality, accountability, equity and trust
while research ethics tends to focus on consent and individ-
ual interests [14]. There are significant similarities between
public health activities, epidemiological research and data
sharing in terms of goals, benefits and risks associated with
these activities. Therefore in this paper we defend a position
that data sharing should be guided by the principles of pub-
lic health ethics than by those of research ethics. We pro-
vide reasons for this position in the later part of the paper.
Health researchers and ethicists have proposed that one
way to promote potential benefits of data sharing and
ameliorate its potential harms would be through the adop-
tion of a managed access approach where requests are
channeled through a Data Access Committee (DAC), rather
than making data openly available without restrictions [15].
DACs, a formal or informal group of individuals who have
the responsibility of reviewing and assessing data access re-
quests [15], have only been developed relatively recently.
Many group, consortia, institutional and independent
DACs have been set up but there is currently no widely ac-
cepted framework under which DACs operate.
This paper aims to suggest a framework for DACs and to
advance discussions on what the functions of these DAC
should be, how they should be organised, and how to con-
stitute them. While many previous discussions have centred
around genomic data, our paper discusses DACs which op-
erate as custodians of all types of health data generated
from public funded health research. The sharing of data
collected in a clinical context or health administrative data,
insurance data is beyond the scope of this paper.
We propose that DACs should have the role of both
promotion of data sharing and protection of data subjects,
their communities, data producers and their institutions.
With these roles in mind, we then discuss the organisation
and composition of a DAC. We suggest that DACs should
not be modelled after research ethics committees (RECs)
and give reasons why. In addition, we suggest that DAC
reviews should be guided by the principles of public health
ethics instead of research ethics.
Main text
Functions of Data Access Committees
Promotion of data sharing in the interest of science, data
producers, data subjects and their communities
We think that given DACs central role in data sharing,
they have an important role in promoting data sharing.
The primary question for a DAC should be whether the
nature, degree, and likelihood of possible public benefits
from the data reuse outweigh the nature, degree and
likelihood of possible harms to the data subjects, rele-
vant communities, or other stakeholders e.g. primary re-
searchers, their institutions, or countries.
The features of ethical primary research studies are
well established. Human subject research guidelines
identify that the first question for any research should
be whether the proposal is likely to generate scientific-
ally sound, socially valuable knowledge [7, 16]. How-
ever, unlike primary research, data access should be
granted as long as the data reuse fulfils the criterion of
having even a minimal social value [7], and minimal
risk to data subjects and their communities (we discuss
risks to primary researchers and their institutions later
in the paper). A critical and skeptical approach to exist-
ing knowledge is an important element of the scientific
enterprise. Therefore, reuse of data does not always
have to generate new knowledge; it is of significant so-
cial value when it verifies results of previous research,
for example. Moreover, the analysis of already existing
data could spur new scientific hypothesis and guide
new research projects [8].
Although data research carries risks, it is not equiva-
lent to enrolling subjects in new clinical or observational
research studies. The nature and magnitude of risks aris-
ing from secondary data use is different from the nature
and magnitude of risks of original studies. This fact is
reflected in many existing international and national reg-
ulations. For instance, in the European Union General
Data Protection Regulation (GDPR) (Art 5(1)(b), Art
89), data-driven health research is given a special dero-
gation and, if researchers demonstrate that a study is “in
the public interest” a REC may grant the study a waiver
of informed consent [17, 18]. Similar standards are
present in the United States Common Rule (45 CFR
§46.116, 45 CFR §164.512) and in the Health Insurance
Portability and Accountability Act (HIPAA) [19], both
regulations grant several derogation for data-driven re-
search involving public benefit, posing minimal risk and
allow access to identifiable health information [20, 21].
For data sharing to be successful, there must be a win-
win situation for both data producers and secondary
data users, their wider teams and institutions. DACs
should encourage secondary uses that promote the inter-
ests of data producers, such as research that contributes
to the goals of their institution [22]. For example, the
DAC for an institution with the goal to improve the
treatment of malaria should encourage data reuse that
ultimately contributes to malaria treatment improve-
ment. However, it does not mean that data should not
be shared if the objective of the secondary use conflicts
with institutional priorities.
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In addition, researchers could reap greater benefits
from their data when others are involved in the second-
ary data analysis (e.g. mathematical modellers). Data
sharing can increase scientific productivity. In most
cases, it is better to collaborate with others than doing it
alone, or planning to conduct the secondary analyses but
never getting to it. These extra outputs that arise as a
direct result of data sharing will help maximise the util-
ity and cost-effectiveness of studies and in turn increase
the overall output and visibility of the institution and its
members. This serves as a powerful internal incentive
for data producers. If they benefit from data sharing,
then data sharing would not be perceived by researchers
as another box to tick or an obligation imposed by fun-
ders and journals.
Many secondary analyses involve research in the same
disease or topic, which could directly benefit the data
subjects and their communities, but there are also many
secondary data uses that will not have these direct bene-
fits. Some data research will confirm existing results,
and others will advance the knowledge of the disease or
topic thereby potentially benefiting future patients in
downstream research. Other data uses could be for
teaching purposes or for shaping a new project. Irre-
spective of how the data are used, provided that there
are some benefits to society, we are respecting the altru-
ism and commitment of data subjects by reusing their
data.
Protecting data subjects, their communities, data producers,
their institutions and the scientific enterprise
Data sharing has triggered concerns for the privacy of
the data subjects. Data scientists have proved on mul-
tiple occasions that datasets that were thought to be
anonymized i.e. “personally identifiable information (PII)
is irreversibly altered in such a way that a PII principal
can no longer be identified directly or indirectly” [23],
could be linked with other public health data to identify
the specific data subject [24, 25]. However, there is
scarce evidence that these individual data breaches have
resulted in individual harms [26]. In fact, many of the
potential harms apply to the data community, rather
than individuals. These potential harms apply even when
data are anonymized, because of potential group harms
be it by geography, disease or ethnicity. Some have
voiced concerns over potential harmful uses that could
result from stigma and discriminatory uses by employers
or insurance companies [14, 27]. Hence, although the
primary role is to promote data sharing, DACs should
also be aware of potential group harms and when such
risks are more than minimal, data reuse should not be
allowed. These potential group harms sometimes depend
on the economic and cultural context of data subjects.
They are more worrying in places that have a history of
targeting and discriminating against minorities, countries
that do not provide their citizens with universal access to
healthcare and where access to healthcare depends on pri-
vate insurance or ability to pay. We recognize that that
DACs do not necessarily know what these group harms will
be. There will be risks of underestimating or misidentifying
potential harms to data subjects and their communities.
These risks can be minimized by careful engagement with
research communities during primary research [28, 29], e.g.
consultation with community leaders and community ad-
visory boards [30–32].
Protection of data subjects also entails protecting their
rights. DACs should make sure that the shared data do
not contain any personally identifiable information, and
that data will be used within the scope of broad consent
provided by subjects. In the case of old datasets where
broad consent for sharing had not been obtained, DACs
should adhere to the criteria set out by CIOMS 2016:
the secondary use offer important otherwise unobtain-
able information, has social value, and poses minimal
risks to the subjects, and that it would be impractical or
prohibitively expensive to contact subjects for their con-
sent for secondary use [7].
There have also been worries that data sharing can
disadvantage data producers and potentially dis-
incentivise primary research [10]. This would be detri-
mental to the research enterprise and scientific progress.
In order to prevent this, DACs should provide guide-
lines, within constraints of funder and regulatory re-
quirements, on when specific conditions of access
should be put in place. These could include recognition
requirements such as authorships, acknowledgements or
standard citations. In some cases, collaborations may be
necessary, especially where interpretation of the data re-
quires the experience of the primary researchers and an
in-depth understanding of the context. In addition, an
institution may have exclusive access periods, require-
ments for benefit sharing, preferential access provisions
(e.g. to collaborators) and embargo periods. In addition,
DACs should mandate when formal data access agree-
ments to specify terms of access should be signed and if
a cost recovery or cost sharing mechanisms should be
put in place.
Establishment, composition and pocedures of a Data
Access Committee
Establishment
The influential Council for International Organization of
Medical Sciences (CIOMS) 2016 guidelines recommend
that “when data are stored, institutions must have a gov-
ernance system to obtain authorisation for these data in
research” [7]. In addition, the guidelines state that “the
ethical acceptability of broad informed consent relies on
proper governance”. Governance of data, which includes
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data access mechanisms is ideally outlined within the in-
stitutional, group or departmental data sharing policy.
We suggest that DACs should be established within in-
stitutional and legal frameworks with clear lines of ac-
countability, terms of reference and membership.
Some suggest that DACs should be independent of the
institution to avoid any conflicts of interest. Indeed
many independent DACs exist for this reason such as
the MalariaGEN and Managing Ethico-social Technical
and Administrative DACs [33, 34]. To motivate data
sharing, we must recognise that sharing data might re-
veal sensitive information not only about data subjects
but also about researchers, healthcare providers and/or
their institutions which might cause harm or embarras-
ment [35]. However, the argument for DACs to be insti-
tutional, instead of completely independent is ultimately
a practical one. If institutions reserve the final authority
regarding data sharing decisions, then they will be more
willing to share their data. Institutions are the custodians
of data and they should act on behalf of research partici-
pants, who have consented to broad research reuse of
their data. Institutional DACs are then accountable to
both their home institution and their research partici-
pants. It is unclear who independent DACs are account-
able to.
Composition
In order to fulfill the functions of a DAC as described in
the previous section, a DAC should consist of a reason-
able number of members, each covering multiple rele-
vant areas of expertise. For DACs of large research
groups, departments or institutions, ideally there should
be members representing senior management, data man-
agement, ethics, relevant research areas and potentially a
data sharing advocate. It is also desirable to have inde-
pendent members to address the issue of conflicts of
interest and to prevent “data hoarding” by researchers
internal to a study.
The CIOMS guidelines state that DAC should have
“representation from the original setting” [7]. In the con-
text of large clinical studies or institutional DACs that
review multiple studies, it is not feasible to have “repre-
sentatives of the original setting” serve as members on
the DAC. However, having members who are familiar
with the context or contexts where the research is con-
ducted is necessary. Some data reuse may require con-
sultation with study investigators, country or community
representatives. DACs can also consult on an ad-hoc
basis with people familiar with the community or data
subjects where necessary.
Application procedures
In order to promote data sharing, there should be trans-
parent, consistent, simple and clear procedures for data
request and data access. The approach to the review of
applications should be proportionate to the potential
risks involved and streamlined because DACs approve
or disapprove data already collected, rather than new re-
search studies. Reviews should be guided by the data
sharing policies of institutions or pre-agreed terms in
the case of independent DACs; and DAC reviews, as we
argue in the next section, should not be guided by re-
view criteria adopted by RECs. Elements of a DAC re-
view should include among other things who is applying,
what are the objectives of data reuse, exactly what data
are requested, anticipated benefits and potential risks.
Why Data Access Committees should not be modelled
after research ethics committees?
One can ask a question, should DACs be modelled after
the RECs (in the US context, known as Institutional Re-
view Boards) system that reviews new human subject re-
search? There are a few organizational and ethical
reasons for devising a different modus operandi for
DACs and these reasons pertain to: organizational cul-
ture; goals of review; ethical framework of review; ac-
countability to the host institution.
Organizational culture
Conceptual analyses and empirical studies reveal that
there is an inbuilt adversarial relationship within the sys-
tem of a research ethics review [36–38]. If the main
function of RECs is to protect research subjects, then
there is an implicit assumption that research poses risks,
and puts the burden of proof that this is not the case on
researchers. As such, researchers do not perceive RECs
members as ethics advisors, but as judges and punishers:
researchers have to prove they have good intentions
[37].
Regulations give RECs a function of protecting re-
search participants by ensuring that they are provided
with proper information and that research projects have
a favourable risk-benefit ratio. However, there is no a
universal standard of how exactly the RECs should func-
tion. Some suggest that RECs should check, if research
protocols are consistent with certain ethical or legal
codes rather than with abstract ethical principles [39];
while others argue that RECs should “perform ethically
informed code consistency review” [40]. As result of
these disagreements, over time the function of protec-
tion has evolved and RECs have acquired new functions,
some of them intended, some were a consequence of in-
stitutional logic and gradual legalisation of ethics reviews
[36]. Hence RECs guard research integrity and quality by
filtering “bad science” projects, and protect community
by screening wasteful and dangerous studies [37]. In this
sense, members of RECs often perceive themselves as
acting on behalf of communities. Moreover, when one
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looks at a REC from a wider perspective and takes into
consideration the fact that their function is grounded in
democratically enacted law, these institutions could also
have a function of providing political and ethical legitim-
acy either to a single study or to biomedical research in
general [41]. Proliferation of functions coupled with in-
consistencies among RECs in multicenter studies have
resulted in growing bureaucratic and financial burden
on researchers. This has led to a recognition that an eth-
ics review might be in certain instances an overprotec-
tion of research subjects that leads to underprotection
[12, 42]. A REC delaying a low-risk study, may at the
same time expose patients to substantial risks, for in-
stance in a situation when a post-marketing study would
provide evidence for serious adverse effects of already
approved drugs [43]. This recognition has been reflected
in the regulations that do not require a full-ethics review
of low-risk studies and the introduction of central re-
views for multicenter studies.
Although an adversarial relationship between RECs
and researchers may be legitimate in riskier clinical tri-
als, an adversarial relationship between DACs and pri-
mary researchers or secondary users is inconsistent with
the desired goals and functions of DACs. As we have ar-
gued, DACs should promote reuse of research data.
DACs should be part of new research culture that helps
in promoting scientific progress. Therefore, the main
function of DACs is not defined in adversarial terms of
“protection”, and DACs should be conceived as an insti-
tution’s tool for realising its goals. Those who apply for
access to data should not be perceived as a potential
danger, but as potential collaborators.
Goals of review
A REC comprising of researchers, lawyers, ethicists,
nurses, patient representatives and community represen-
tatives is intended to bring a diverse perspective on sci-
entific and ethical aspects of a study involving human
beings. The goals of an ethics review are to discern those
aspects of a study that were overlooked or misjudged by
a researcher whose perspective might be skewed by con-
flicting interests, and to ensure that the research com-
plies with specific laws and research ethics guidelines.
A REC may work in accordance with either a panel of
professionals or a jury board [44]. In the case of a pro-
fessional panel, a REC adjudicates from the position of a
professional and objective judge; in the case of a jury
board, a REC makes its decision from the point of view
of a reasonable layperson. The main goal of ethics re-
view is to protect research participants, and although it
is the principal investigator and sponsor who bear the
ultimate responsibility for the well-being of research
subjects, RECs are at least morally responsible too.
RECs review new research studies and any secondary
data research that requires ethical approval which can
differ from jurisdiction to jurisdiction. DACs review data
access requests for secondary uses. These uses may be
for secondary data research but could also be for teach-
ing purposes, to confirm the findings of the original ana-
lyses or other purposes. DACs roles should not include
full review of the secondary research such as method-
ology of the secondary research and the statistical ap-
proaches. That is the job of RECs.
The secondary use of data already collected differs sig-
nificantly from conducting clinical research. A secondary
data user does not interact with research subjects; data
research does not require additional diagnostic tests or
examinations and the possible risks to an individual are
often limited to privacy breaches and group harms.
DACs have different objectives from RECs. DACs are
custodians of research data, but this function cannot be
understood as a protection from intruders, who may
want to have a peek into their treasure trove, but pro-
moters of the beneficial use of data. Institutional DACs
should also review the consistency of data use with insti-
tutional data sharing policies. The goal of this review
should include maximising data research utility either by
confirming previously tested results or generating new
data, and assessing if there are any potential harms to all
relevant stakeholders.
Ethical framework for review
In its origins, research ethics has been informed by the
scandals and tragedies of research, such as atrocities of
Nazi doctors, the Willowbrook School Experiment, the
Jewish Chronic Disease Hospital and the Tuskegee syph-
ilis studies [11]. Due to these historical events, the main
goal of research ethics framework and resulting guidance
documents was protection of individual research partici-
pants. Moreover, those who were conducting medical re-
search were physicians themselves, whose professional
identity was intrinsically connected with an obligation to
protect and promote individual patient interests. This is
why many research ethics guidelines, such as the Oviedo
Convention [45] and the Declaration of Helsinki [16],
contain some version of the principle of precedence of
individual interests, for example, “the interests of an in-
dividual should prevail over the sole interest of society
or science” [46]. However, it has become clear recently,
that the principles of research ethics cannot be universa-
lised, and not all kinds of research can be held to the
same ethical and procedural standards. For instance, an
ethical review and an informed consent procedure may
seriously impede multicentre epidemiological studies
[47]. The goals of epidemiology and public health are
different than those of clinical research. The main focus
of epidemiology and public health is not an individual
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patient, but promotion of population health [48].
Moreover, in public health research it is much more
difficult to distinguish research from routine clinical
practice [13, 49, 50].
Similar problems of inadequacy of the research ethics
approach to multicenter data-driven research has been
recently discussed in regards to learning healthcare sys-
tems (LHS), in which conducting research is embedded
into healthcare practice [12, 42]. The learning process is
driven by data that are produced in healthcare practice
and then collected and analysed in a search for general-
isable knowledge. Efficiency of LHS requires a different
ethical approach. Here again protection of an individual
is not a priority, since an individual patient is not ex-
posed to risks other than those inherently associated
with healthcare practice. The conceptual and ethical
framework for LHS also applies to principles of public
health ethics rather than research ethics - to weigh pub-
lic benefits against possible infringements of individual
rights [12, 13, 48].
Epidemiology, public health research, and LHSs have a
few common characteristics: the benefits and risks per-
tain to groups rather than to individuals; in many cases
the research activity consists of collecting and analyzing
vast volumes of data; research ethics standards (e.g. full-
informed consent, full-ethics review) are not feasible and
can either hamper research or put extra bureaucratic
burden on researchers. In all three cases it is clear that
the public health ethics approach is applied. Data shar-
ing, at least in two important respects, has similar char-
acteristics to epidemiology, LHS and public health
research: the benefits and risks of data sharing pertain to
groups rather than to individuals, and data sharing is
about accessing and processing vast volumes of data and
there are minimal additional risks to a data subject.
Taken together, the more suitable ethical approach to
data sharing should be that of public health ethics in-
stead of research ethics [14].
Accountability to host institution
There are at least two models of a REC: independent
bodies established by private or public actors, or RECs
that are established by research institutions such as uni-
versities. Both models provide independent review of re-
search studies. Independence does not mean that there
is no institutional links between a REC and a research
institution, but it means that the research institution
does not influence the workings of its REC which should
be independent in its judgments of the ethical standards
of studies. Importantly, RECs do not implement any in-
stitutional research policies nor are they tasked to pro-
mote research.
We think that DACs should play a central role in
implementing institutional policies on data sharing. This
is yet another reason for DACs to be institutional rather
than independent. The task of a DAC is to balance the
goals and policies of its institutions, the goals and inter-
ests of those who apply for data and the public good.
RECs protect research subjects by applying ethical prin-
ciples and rules of law; DACs should promote data shar-
ing while mitigating any potential risks, and should be a
mechanism to implement institutional data sharing pol-
icies. While it is challenging to evaluate the efficacy and
efficiency of RECs, it is possible to evaluate those of a
DAC, that is by measuring the realisation of data sharing
goals and policies.
Strengths and limitations
Our normative proposal is supported by experience of
establishing and coordinating the Mahidol Oxford Trop-
ical Medicine Research Unit (MORU) DAC, which has
reviewed over 40 applications since its establishment in
January 2016 [51–53]. The MORU DAC has reviewed
many types of data requests including data in real time
from an ongoing clinical study, from historical trials
done without participant consent for data sharing, and
from pharmaceutical companies for data from trials con-
ducted in low-resource settings for registering products
in developed countries [52, 54].
Our suggestions are primarily focused on DACs of
publicly funded large research groups, departments or
institutions conducting clinical research. We acknow-
ledge that some research groups may be too small
and may not have the resources or skills to establish
and run their own DACs. Efforts are underway to
provide support for research groups in low-resource
settings to establish their own data sharing policies
and DACs. We think that future empirical research is
needed to verify the feasibility and efficacy our sug-
gestions, and compare them with other models of
DACs such as DACs established to review requests
for health system data.
Conclusions
In this paper we have suggested a framework for the
functions and establishment of DACs and demonstrated
that sharing de-identified health data should be gov-
erned by a different conceptual and ethical framework
than clinical research involving human beings. DACs
should promote the beneficial use of data, while mitigat-
ing any potential harms in line with the ethical frame-
work for public health instead of research ethics. We
have also argued that the system of ethics review as it is
operated by RECs is not suitable for the realizing the
ideals of data sharing and therefore should not be a
model for DACs.
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